• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Call on Congress 2014 John Marshall, Treatment
 

Call on Congress 2014 John Marshall, Treatment

on

  • 175 views

Treatment: It’s no longer “one size fits all”

Treatment: It’s no longer “one size fits all”
John Marshall, MD, Georgetown University Medical Center

Statistics

Views

Total Views
175
Views on SlideShare
175
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Call on Congress 2014 John Marshall, Treatment Call on Congress 2014 John Marshall, Treatment Presentation Transcript

    • Fighting a Smarter War On Colon Cancer: John L. Marshall, MD Value as a new endpoint? Tel: (202) 444-0275 Fax: (202) 444-1229 http://lombardi.georgetown.edu/GI
    • Stakeholder  Mo-va-on     Stakeholders   •  FDA   •  CMS/Payers   •  NCI/CTEP   •  PhRMA   •  Community  Onc   •  Academic  Onc   •  Pa>ents   Priority/Agenda   •  Safety  and  Efficacy   •  Cost  Control/Value   •  Cure  Cancer   •  Markets,  ROI   •  Efficient/Quality  Care   •  Clinical  Trial  Accrual   •  Cure/Benefit/Altruism  
    • Stakeholder  Mo-va-on     Stakeholders   •  FDA   •  CMS/Payers   •  NCI/CTEP   •  PhRMA   •  Community  Onc   •  Academic  Onc   •  Pa>ents   Priority/Agenda   •  Safety  and  Efficacy   •  Cost  Control/Value   •  Cure  Cancer   •  Markets,  ROI   •  Efficient/Quality  Care   •  Clinical  Trial  Accrual   •  Cure/Benefit/Altruism  
    • Worldwide  Cancers  Sta>s>cs F.  Bray  et  al,  Lancet  Oncol  2012;  13:  790–801  and  h"p://www.cancer.org/aboutus/globalhealth.       2030  values  are  es>mated    using  projected  incidence  and  mortality  rates    from  2008  to  2030  and   weigh>ng  for  prevalence  in  developed  compared  to  developing  countries.   GI   2008   0   1000000   2000000   3000000   4000000   5000000   6000000   7000000   0   1000000   2000000   3000000   4000000   5000000   6000000   7000000   2030   Breast   Prostate   Lung   Lung   Prostate   Breast   GI  
    • Gastrointestinal (GI) Cancers Facts v GI cancers represent the most common and fatal cancers in the world v 2009: 275,720 new diagnosis of GI Cancers and 135,830 deaths in the US alone v Anal Cancer v Colorectal Cancer v Esophageal Cancer v Gallbladder Cancer v Liver Cancer v Pancreatic Cancer v Small Intestine Cancer v Stomach/Gastric Cancer v No two cancers are alike and treatments must be selected based on an individual’s tumor characteristics, by personalized medicine
    • Breast Cancer Nation
    • Why Not Brown?
    • Value Safety and Efficacy
    • Our Current Model of Colon Cancer
    • Antoni van Leeuwenhoek (1632-1723) Invented the microscope around 1668 10
    • The view from 35,000 feet Everything looks the same from up here
    • What can we predict?
    • Standard  of   Care   New   Pa>ent   Diagnosis  /   staging   Standard   Chemotherapy   Hope  for   the  best   30%  chance   of    any   response  
    • Cancer is driven by hyperactive or defective protein circuits The components of these circuits contain the drug targets of the future. Patient A Patient B Each patient’s cancer is different. A drug that works for one patient may not work for another patient with the same cancer.
    • Ruesch  Symposia:   •  2010  Biomarkers:  Can  we  measure  them?   •  2011  Defining  Value  in  Cancer   •  2012  Clinical  Research:  Engaging  the  97%   •  2013  Molecular  Profiling:Research/ Prac>ce  
    • Hypothesis   Prospec>ve  incorpora>on  of   molecular  profiling  will   transform  global  cancer  care  
    • Personalized   Medicine   New   Pa>ent   Diagnosis   /  staging   HER2 ↑ TS ↓ TOP1 ↑ KRAS ↑ ERCC1 ↓ SPARC ↑ B-RAF ↑ PGP ↓ CURE? Targeted   Therapy   Personalized   Therapy   ↑   Response   Molecular-­‐   Tailored   Therapy  
    • GI  Cancer   Pa>ents   Smart Centers Profile  All   Treatment   Outcomes   Unified   CRF/EMR   BioBank   Team   Central   Imaging   Central   Consent   Data  Cloud:    Shared  &  IP  Protected     Managed  by  DSM,   STATS    HIPPA  compliant,   Regulatory Review Cancer   Centers   Profilers   Pharma  +   Guidelines  
    • Fundamental  Shies  In  Cancer  Care   Yesterday   • Consump>on   • Individual  Prac>ces   • Rich  Countries   • Microscope   • Safety  and  Efficacy   • Large  trials   • 1.4  months   • QOL   • Pa>ent  as  a  “Subject”   • Chao>c  Data  Collec>on   • Ins>tu>onal  IRBs   • Na>onal  Approvals   Tomorrow   • Outcomes   • Healthcare  Systems   • All  Countries   • Gene  Profile   • Value   • Small  trials   • “Substan>al  Improvement”   • Pa>ent  Reported  Outcomes   • Pa>ent  as  a  “Partner”   • Standard  Data  Collec>on   • Central/Na>onal  IRBs   • Global  Approvals